Biomaterial Database

Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison. 1985

J F Chantot, and A Bryskier

Ofloxacin (DL8280, RU43280) is a newly introduced oxazine quinolone derivative with broad and potent antibacterial activity. Ofloxacin showed excellent in-vitro activity against Enterobacteriaceae while most strains of Pseudomonas aeruginosa were inhibited by less than 2 mg/l. The compound was significantly more potent than norfloxacin against Acinetobacter spp. and Staphylococcus spp. Ofloxacin and norfloxacin behaved similarly with respect to inoculum size, effect of urine and serum, bactericidal properties and frequency of spontaneous resistant mutants. Ofloxacin displayed an in-vivo antibacterial activity up to five times greater than that of pefloxacin and norfloxacin, probably due to the conjunction of favourable pharmacokinetics, excellent bacterial susceptibility and good stability towards metabolic degradation.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008826	Microbial Sensitivity Tests	Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).	Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009268	Nalidixic Acid	A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE.	Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D009643	Norfloxacin	A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.	AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D010078	Oxazines	Six-membered heterocycles containing an oxygen and a nitrogen.
D011485	Protein Binding	The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.	Plasma Protein Binding Capacity,Binding, Protein
D001798	Blood Proteins	Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.	Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D004352	Drug Resistance, Microbial	The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).	Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000900	Anti-Bacterial Agents	Substances that inhibit the growth or reproduction of BACTERIA.	Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

J F Chantot, and A Bryskier

The comparative in vitro activity of ofloxacin (RU 43 280) and other quinolone derivatives against 722 bacteria of clinical interest.

June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,

J F Chantot, and A Bryskier

Synthesis and in vitro antibacterial activity of quinolone/naphthyridone derivatives containing 3-alkoxyimino-4-(methyl)aminopiperidine scaffolds.

March 2013, Bioorganic & medicinal chemistry letters,

J F Chantot, and A Bryskier

In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.

November 1985, The Journal of antimicrobial chemotherapy,

J F Chantot, and A Bryskier

In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.

January 1988, Chemotherapy,

J F Chantot, and A Bryskier

[Comparison of the in vitro antibacterial activity of ofloxacin and nalidixic acid].

July 1990, Mikrobiyoloji bulteni,

J F Chantot, and A Bryskier

In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.

December 1984, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,

J F Chantot, and A Bryskier

Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.

January 2022, Bioorganic & medicinal chemistry letters,

J F Chantot, and A Bryskier

In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.

October 1988, The Journal of antimicrobial chemotherapy,

J F Chantot, and A Bryskier

Metronidazole-quinolone combination: antibacterial activity in vitro.

October 1985, Pharmacological research communications,

J F Chantot, and A Bryskier

In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

June 1986, Antimicrobial agents and chemotherapy,